Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4140/TCP.n.2021.238 http://scihub22266oqcxt.onion/10.4140/TCP.n.2021.238 33879284!ä!33879284 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\33879284.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Sr+Care+Pharm 2021 ; 36 (5): 238-241 Nephropedia Template TP {{tp|p=33879284|t=2021. A Review of Topical Povidone-iodine to Decrease Viral Load of COViD-19 |pdf=|usr=}}{{33879284}} gab.com Text A Review of Topical Povidone-iodine to Decrease Viral Load of COViD-19 JO: Sr Care Pharm http://www.kidney.de/pget.php?&tw=1&pmid=33879284 #FOAvip Topical povidone-iodine (PVP-I) is currently being considered as a potential preventive measure against the spread of COVID-19. Diluted PVP-I solutions have been historically used in Asia to treat upper respiratory tract infections (URTIs) by decreasing the bacterial and viral load on oropharyngeal mucosa to decrease the transmission of diseases. Efficacy of gargling 0.23% PVP-I mouthwash in Japan demonstrated to be efficacious in lowering the prevalence of URTIs when compared with placebo. The 0.23% concentration was used in vitro on severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, which produced undetectable results after 30 seconds of exposure. Additionally, a recent study in 2020 proved the efficacy of PVP-I 0.45%-10% in reducing COVID-19 (SARS-CoV 2) viral load in vitro. Numerous clinical trials are being conducted to determine if there is a decrease in viral load, and thus transmission, when using oral or nasal topical PVP-I in COVID-19 patients. Because of the current lack of evidence for the use of PVP-I in vivo with COVID-19, it is recommended to await the clinical trial results before initiating this practice. Twit Text FOAVip A Review of Topical Povidone-iodine to Decrease Viral Load of COViD-19 ????Sr Care Pharm http://www.kidney.de/pget.php?&tw=1&pmid=33879284 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33879284 #FOAvip English Wikipedia <ref>{{Cite pmid|33879284}}</ref> A Review of Topical Povidone-iodine to Decrease Viral Load of COViD-19 #MMPMID33879284 Benson KM; Mancini AA; Brodeur MR Sr Care Pharm 2021[May]; 36 (5): 238-241 PMID33879284show ga Topical povidone-iodine (PVP-I) is currently being considered as a potential preventive measure against the spread of COVID-19. Diluted PVP-I solutions have been historically used in Asia to treat upper respiratory tract infections (URTIs) by decreasing the bacterial and viral load on oropharyngeal mucosa to decrease the transmission of diseases. Efficacy of gargling 0.23% PVP-I mouthwash in Japan demonstrated to be efficacious in lowering the prevalence of URTIs when compared with placebo. The 0.23% concentration was used in vitro on severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, which produced undetectable results after 30 seconds of exposure. Additionally, a recent study in 2020 proved the efficacy of PVP-I 0.45%-10% in reducing COVID-19 (SARS-CoV 2) viral load in vitro. Numerous clinical trials are being conducted to determine if there is a decrease in viral load, and thus transmission, when using oral or nasal topical PVP-I in COVID-19 patients. Because of the current lack of evidence for the use of PVP-I in vivo with COVID-19, it is recommended to await the clinical trial results before initiating this practice. |*Anti-Infective Agents, Local[MESH] |*COVID-19[MESH] |Humans[MESH] |Povidone[MESH] |Povidone-Iodine/pharmacology[MESH] |SARS-CoV-2[MESH]A Review of Topical Povidone-iodine to Decrease Viral Load of COViD-19(epmc).pdf DeepDyve Pubget Overpricing